Publicaciones en las que colabora con María Mar Fernández Gatta García (22)

2016

  1. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma

    British Journal of Clinical Pharmacology, Vol. 82, Núm. 6, pp. 1517-1527

2014

  1. Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 955-956, Núm. 1, pp. 93-97

2010

  1. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy

    Therapeutic Drug Monitoring, Vol. 32, Núm. 5, pp. 579-585

2009

  1. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280

2005

  1. Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies

    Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941

2003

  1. Predicción de la absorción de medicamentos por vía oral: aplicación de modelos "in sílico"

    Anales de la Real Academia de Medicina y Cirugía de Valladolid, Núm. 41, pp. 89-100

2002

  1. Immunosuppressive therapy for paediatric transplant patients: Pharmacokinetic considerations

    Clinical Pharmacokinetics, Vol. 41, Núm. 2, pp. 115-135

1997

  1. Population pharmacokinetics of caffeine in premature neonates

    European Journal of Clinical Pharmacology, Vol. 52, Núm. 3, pp. 211-217

1996

  1. Bayesian Forecasting in Paediatric Populations

    Clinical Pharmacokinetics, Vol. 31, Núm. 5, pp. 325-330

  2. Bayesian forecasting in paediatric populations

    Clinical Pharmacokinetics

  3. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies

    Clinical Pharmacology and Therapeutics, Vol. 60, Núm. 3, pp. 332-340

1993

  1. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies

    Clinical Pharmacy, Vol. 12, Núm. 7, pp. 515-520

1992

  1. Dosage optimization methods applied to imipramine and desipramine in enuresis treatment

    Journal of Clinical Pharmacy and Therapeutics, Vol. 17, Núm. 1, pp. 55-59

  2. Population pharmacokinetics of imipramine in children

    European Journal of Clinical Pharmacology, Vol. 43, Núm. 1, pp. 89-92

1990

  1. The influence of clinical and pharmacological factors on enuresis treatment with imipramine.

    British Journal of Clinical Pharmacology, Vol. 30, Núm. 5, pp. 693-698

1989

  1. Prediction of Imipramine Serum Levels in Enuretic Children by a Bayesian Method

    Therapeutic Drug Monitoring, Vol. 11, Núm. 6, pp. 637-641

  2. Predictive techniques applied to imipramine therapeutic drug monitoring

    DICP, Annals of Pharmacotherapy, Vol. 23, Núm. 5, pp. 389-394

1988

  1. High levels of tricyclic antidepressants in conventional therapy: determinant factors

    International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 26, Núm. 10, pp. 495-499

1986

  1. Effect of Sodium Valproate on Phenobarbital Serum Levels in Children and Adults

    Therapeutic Drug Monitoring, Vol. 8, Núm. 4, pp. 416-420

1985

  1. INTOXICACION POR ANTIDEPRESIVOS TRICICLICOS

    Farmacia Clinica, Vol. 2, Núm. 6, pp. 9-30